These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 23296792

  • 41. FGF-23 in patients with end-stage renal disease on hemodialysis.
    Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y.
    Kidney Int; 2004 May; 65(5):1943-6. PubMed ID: 15086938
    [Abstract] [Full Text] [Related]

  • 42. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.
    Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M.
    N Engl J Med; 2008 Aug 07; 359(6):584-92. PubMed ID: 18687639
    [Abstract] [Full Text] [Related]

  • 43. Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial.
    Sigrist M, Tang M, Beaulieu M, Espino-Hernandez G, Er L, Djurdjev O, Levin A.
    Nephrol Dial Transplant; 2013 Jan 07; 28(1):161-9. PubMed ID: 23024219
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation.
    Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R, Schiavi SC, Slatapolsky E, Brown AJ.
    Nephron Physiol; 2006 Jan 07; 104(1):p23-32. PubMed ID: 16691036
    [Abstract] [Full Text] [Related]

  • 46. Fibroblast Growth Factor-23 and Carotid Artery Intima Media Thickness in Chronic Kidney Disease.
    Yilmaz G, Ustundag S, Temizoz O, Sut N, Demir M, Ermis V, Sevinc C, Ustundag A.
    Clin Lab; 2015 Jan 07; 61(8):1061-70. PubMed ID: 26427152
    [Abstract] [Full Text] [Related]

  • 47. [Fibroblast growth factor 23 and a novel high-sensitivity troponin I: Early markers and alternative ways of damaging the heart in chronic kidney disease].
    Dzgoeva FU, Sopoev MY, Gatagonova TM, Bestaeva TL, Khamitsaeva OV.
    Ter Arkh; 2015 Jan 07; 87(6):68-74. PubMed ID: 26281199
    [Abstract] [Full Text] [Related]

  • 48. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
    Toussaint ND, Pedagogos E, Tan SJ, Badve SV, Hawley CM, Perkovic V, Elder GJ.
    Nephrology (Carlton); 2012 Jul 07; 17(5):433-44. PubMed ID: 22574672
    [Abstract] [Full Text] [Related]

  • 49. FGF-23: More than a regulator of renal phosphate handling?
    Jüppner H, Wolf M, Salusky IB.
    J Bone Miner Res; 2010 Oct 07; 25(10):2091-7. PubMed ID: 20593414
    [Abstract] [Full Text] [Related]

  • 50. Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
    Adema AY, de Borst MH, Ter Wee PM, Vervloet MG, NIGRAM Consortium.
    J Ren Nutr; 2014 May 07; 24(3):143-50. PubMed ID: 24216259
    [Abstract] [Full Text] [Related]

  • 51. Relationship between Fibroblast Growth Factor 23 and Biochemical and Bone Histomorphometric Alterations in a Chronic Kidney Disease Rat Model Undergoing Parathyroidectomy.
    Liao HW, Hung PH, Hsiao CY, Liou HH, Lin HS, Huang TH, Jou IM, Tsai KJ.
    PLoS One; 2015 May 07; 10(7):e0133278. PubMed ID: 26186634
    [Abstract] [Full Text] [Related]

  • 52. Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study.
    Yasin A, Liu D, Chau L, Madrenas J, Filler G.
    BMC Nephrol; 2013 Feb 17; 14():39. PubMed ID: 23413976
    [Abstract] [Full Text] [Related]

  • 53. FGF-23 and cardiovascular disease: review of literature.
    Batra J, Buttar RS, Kaur P, Kreimerman J, Melamed ML.
    Curr Opin Endocrinol Diabetes Obes; 2016 Dec 17; 23(6):423-429. PubMed ID: 27652999
    [Abstract] [Full Text] [Related]

  • 54. Diabetes modifies effect of high-phosphate diet on fibroblast growth factor-23 in chronic kidney disease.
    Muras K, Masajtis-Zagajewska A, Nowicki M.
    J Clin Endocrinol Metab; 2013 Dec 17; 98(12):E1901-8. PubMed ID: 24092829
    [Abstract] [Full Text] [Related]

  • 55. [Role of fibroblast growth factor 23 in the development of cardiovascular diseases in patients with end-stage renal failure on programmed hemodialysis].
    Dzgoeva FU, Sopoev MY, Bestaeva TL, Khamitsaeva OV, Ktsoeva FA, Sageeva RO.
    Ter Arkh; 2016 Dec 17; 88(12):51-56. PubMed ID: 28139560
    [Abstract] [Full Text] [Related]

  • 56. The relationship between FGF-23 and ghrelin levels in CKD patients: preliminary data.
    Ozturk S, Ozkan O, Efe M, Yazici H, Gursu M, Kaya AH, Cebeci E, Sumnu A, Karadag S, Poturoglu S, Kazancioglu R.
    Minerva Urol Nefrol; 2016 Apr 17; 68(2):227-32. PubMed ID: 26125281
    [Abstract] [Full Text] [Related]

  • 57. Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients.
    Sugimoto H, Ogawa T, Iwabuchi Y, Otsuka K, Nitta K.
    Int Urol Nephrol; 2014 Jan 17; 46(1):99-106. PubMed ID: 23355029
    [Abstract] [Full Text] [Related]

  • 58. Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis.
    Nakano C, Hamano T, Fujii N, Obi Y, Matsui I, Tomida K, Mikami S, Inoue K, Shimomura A, Nagasawa Y, Okada N, Tsubakihara Y, Rakugi H, Isaka Y.
    Bone; 2012 Jun 17; 50(6):1266-74. PubMed ID: 22425694
    [Abstract] [Full Text] [Related]

  • 59. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis.
    Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D.
    J Biol Chem; 2014 Apr 04; 289(14):9795-810. PubMed ID: 24509850
    [Abstract] [Full Text] [Related]

  • 60. The value of serum FGF-23 as a cardiovascular marker in HD patients.
    Sany D, Elsawy AE, Aziz A, Elshahawy Y, Ahmed H, Aref H, El Rahman MA.
    Saudi J Kidney Dis Transpl; 2014 Jan 04; 25(1):44-52. PubMed ID: 24434381
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.